Article
Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance
1 May 2011
Abstract excerpt
Sitamaquine is a 8-aminoquinoline in development for the treatment of visceral leishmaniasis by oral route, no activity being observed on the experimental cutaneous leishmaniasis experimental models. Recent data explain how sitamaquine accumulate in Leishmania parasites, however its molecular targets remain to be identified. An advantage of sitamaquine is its short elimination half-life, preventing a rapid...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
